M
Martina Schäfer
Researcher at Bayer
Publications - 17
Citations - 496
Martina Schäfer is an academic researcher from Bayer. The author has contributed to research in topics: In vivo & Cancer. The author has an hindex of 9, co-authored 17 publications receiving 350 citations. Previous affiliations of Martina Schäfer include Bayer Corporation & Bayer HealthCare Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
Ulrich Lücking,Arne Scholz,Philip Lienau,Gerhard Siemeister,Dirk Kosemund,Rolf Bohlmann,Hans Briem,Terebesi Ildiko,Kirstin Meyer,Katja Prelle,Karsten Denner,Ulf Bömer,Martina Schäfer,Knut Eis,Ray Valencia,Stuart Ince,Franz von Nussbaum,Dominik Mumberg,Karl Ziegelbauer,Bert Klebl,Axel Choidas,Peter Nussbaumer,Matthias Baumann,Carsten Schultz-Fademrecht,Gerd Rühter,Jan Eickhoff,Michael Brands +26 more
TL;DR: BAY 1143572 is the first potent and highly selective PTEFb/CDK9 inhibitor to enter clinical trials for the treatment of cancer.
Journal ArticleDOI
A New, Practical One-Pot Synthesis of Unprotected Sulfonimidamides by Transfer of Electrophilic NH to Sulfinamides.
TL;DR: This new reaction provides a safe, short and efficient approach to sulfonimidamides, which have been the subject of recent, growing interest in the life sciences.
Journal ArticleDOI
Equilibrium, 1H and 13C NMR spectroscopy, and X-ray diffraction studies on the complexes Bi(DOTA)- and Bi(DO3A-Bu).
Éva Csajbók,Zsolt Baranyai,István Bányai,Ernö Brücher,Róbert Király,Anke Muller-Fahrnow,Johannes Platzek,Bernd Radüchel,Martina Schäfer +8 more
TL;DR: It was shown by (1)H and (13)C NMR spectroscopy that the OH group attached to the middle carbon atom of the "butriol" side chain is coordinated to the Bi(III) and starts to deprotonate at pH > 5.5.
Journal ArticleDOI
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
Franz von Nussbaum,Volkhart Min-Jian Li,Swen Allerheiligen,Sonja Anlauf,Lars Bärfacker,Martin Bechem,Martina Delbeck,Fitzgerald Mary F,Michael Gerisch,Heike Gielen-Haertwig,Helmut Haning,Dagmar Karthaus,Dieter Lang,Klemens Lustig,Daniel Meibom,Joachim Mittendorf,Ulrich Rosentreter,Martina Schäfer,Stefan Schäfer,Jens Schamberger,Leila Telan,Adrian Tersteegen +21 more
TL;DR: A novel dihydropyrimidinone lead‐structure class was identified and was shown to be efficacious in a rodent animal model related to ALI, and is currently being tested in clinical studies for the treatment of pulmonary diseases.
Journal ArticleDOI
Exploration of Novel Chemical Space: Synthesis and in vitro Evaluation of N-Functionalized Tertiary Sulfonimidamides.
TL;DR: The described N‐functionalization reactions provide a short and efficient approach to structurally diverse sulfonimidamides which have been the subject of recent, growing interest in the life sciences.